ITGA7基因与人类肿瘤的泛癌分析

doi:10.19586/j.2095-2341.2024.0073

生物技术进展 ›› 2025, Vol. 15 ›› Issue (1): 142-151.DOI: 10.19586/j.2095-2341.2024.0073

• 研究论文 • 上一篇

ITGA7基因与人类肿瘤的泛癌分析

甄思斌(), 车逸宁, 王晓, 李冕()

山东第一医科大学生物医学科学学院，济南 250000

收稿日期:2024-04-08 接受日期:2024-06-03 出版日期:2025-01-25 发布日期:2025-03-07
通讯作者: 李冕
作者简介:甄思斌 E-mail: 1977663477@qq.com；
基金资助:
山东第一医科大学（山东省医学科学院）青年科学基金项目(202201-006)

Pan Cancer Analysis Between ITGA7 Gene and Human Tumors

Sibin ZHEN(), Yining CHE, Xiao WANG, Mian LI()

School of Biomedical Sciences，Shandong First Medical University，Jinan 250000，China

Received:2024-04-08 Accepted:2024-06-03 Online:2025-01-25 Published:2025-03-07
Contact: Mian LI

摘要/Abstract

摘要：

探究了ITGA7基因在人类肿瘤中的基因及蛋白表达水平，并评估其临床意义。通过cBioPortal、GEPIA2、Timer2.0、STRING和Veen等多种数据库分析ITGA7的变异情况、与肿瘤预后之间的关系、基因表达与免疫浸润的关联性以及功能富集分析。发现在肝癌（liver cancer，LIHC）、肾透明细胞癌（clear cell carcinoma of kidney，KIRC）、甲状腺癌（thyroid cancer，THCA）等肿瘤组织中ITGA7表达量升高与不良预后存在关联，相反，ITGA7在子宫内膜癌（endometrial cancer，UCEC）、前列腺癌（prostatic cancer,PRAD）、直肠癌（rectal cancer，READ）、乳腺癌（breast cancer，BRCA）、肺鳞癌（lung squamous carcinoma，LUSC）等肿瘤组织中表达量较低，且其低表达与胰腺癌的不良预后相关。ITGA7主要变异类型为错义突变。在结肠癌（colon cancer，COAD）、膀胱癌（carcinoma of urinary bladder,BLCA）、乳腺癌等6种肿瘤中，ITGA7的表达量与免疫浸润水平呈正相关，而在肉瘤中的表达量与免疫浸润水平呈负相关。泛癌分析显示ITGA7的表达与免疫浸润水平、基因突变及肿瘤预后相关，这一发现有助于从临床角度深入理解ITGA7在肿瘤发生和发展中的潜在作用，并为临床诊断与治疗提供参考。

关键词: ITGA7基因, 癌症, 泛癌分析

Abstract:

This study aimed to explore the gene and protein expression levels of ITGA7 gene in human tumors and evaluate its clinical significance. The variation of ITGA7， its relationship with tumor prognosis， the correlation between gene expression and immune infiltration， and functional enrichment analysis were analyzed through various databases such as cBioPortal， GEPIA2， Timer2.0， STRING and Veen. It was found that increased expression of ITGA7 in tumor tissues such as liver cancer， renal clear cell carcinoma， and thyroid cancer was associated with poor prognosis. On the contrary， ITGA7 expression in tumor tissues such as endometrial cancer， prostate cancer， rectal cancer， breast cancer， and lung squamous cell carcinoma was found to be associated with poor prognosis. The expression of ITGA7 is low in pancreatic cancer， and its low expression is associated with poor prognosis of pancreatic cancer. The main mutation type of ITGA7 is missense mutation. In six types of tumors， including colon cancer， bladder cancer， and breast cancer， the expression of ITGA7 was positively correlated with the level of immune infiltration， while the expression in sarcomas was negatively correlated with the level of immune infiltration. Pan-cancer analysis showed that the expression of ITGA7 is related to the level of immune infiltration， gene mutations and tumor prognosis. This finding helps to deeply understand the potential role of ITGA7 in tumor occurrence and development from a clinical perspective， and provides a reference for clinical diagnosis and treatment.

Key words: ITGA7, cancer, pan-cancer analysis

中图分类号:

Q345

甄思斌, 车逸宁, 王晓, 李冕. ITGA7基因与人类肿瘤的泛癌分析[J]. 生物技术进展, 2025, 15(1): 142-151.

Sibin ZHEN, Yining CHE, Xiao WANG, Mian LI. Pan Cancer Analysis Between ITGA7 Gene and Human Tumors[J]. Current Biotechnology, 2025, 15(1): 142-151.

图/表 6

图1 ITGA7基因在不同肿瘤和病理学阶段的表达分析A：TIMER2.0分析显示ITGA7基因在不同肿瘤的表达，*、**、***分别表示数据在P<0.05、P<0.01、P<0.001水平有统计学差异；B：GEPIA2分析ITGA7在10种不同类型肿瘤的表达，*—数据在P<0.05水平有统计学差异；C：ITGA7在不同阶段肿瘤的表达水平。Log2（TPM+1）转化处理分析。

Fig. 1 Expression analysis of ITGA7 gene in different tumor and pathological stages

图2 ITGA7基因与不同肿瘤生存预后的相关性A：利用GEPIA2对不同肿瘤总体生存期（OS）的生存预后呈现；B：利用GEPIA2对不同肿瘤无病生存期（DFS）的生存预后呈现。

Fig. 2 Correlation between ITGA7 gene and survival prognosis of different tumors

图3 ITGA7基因在TCGA不同肿瘤中的变异情况A：ITGA7基因在不同癌症或在特定癌症亚型中的突变类型；B：ITGA7突变位点的蛋白三维结构；C：显示了ITGA7基因突变频率最高的突变位点；D：ITGA7突变状态与UCEC整体、疾病特异性、无病生存和无进展生存之间的潜在相关性。

Fig. 3 Variation of ITGA7 gene in different TCGA tumors

图4 ITGA7基因表达与肿瘤相关成纤维细胞免疫浸润的分析结果A：ITGA7与肿瘤相关成纤维细胞浸润的相关性热图；B：ITGA7基因表达与肿瘤相关成纤维细胞浸润的相关性分析。通过不同算法研究ITGA7基因的表达水平与TCGA中所有类型肿瘤的肿瘤相关成纤维细胞的浸润水平之间的潜在关系。

Fig. 4 Analysis results of ITGA7 gene expression and tumor-associated fibroblast immune infiltration

图5 ITGA7相关基因的富集分析A：50个有实验验证的ITGA7结合蛋白；B：TCGA中前100个ITGA7相关基因，以及被选定的靶向基因之间的表达相关性，包括CFL2、CSRP1、FERMT2、JPH2和RASL12；C：上述五种基因与ITGA7的相关性热图；D：相关基因和ITGA7结合基因的交叉分析

Fig. 5 Enrichment analysis of ITGA7-related genes

图6 ITGA7相关基因的KEGG和GO分析A：基于ITGA7结合和互作基因的KEGG富集分析；B：基于ITGA7结合和互作基因的GO分析；C~D：GO分析中的相互作用网络。

Fig. 6 KEGG and GO analysis of ITGA7-related genes

参考文献 28

1	YUAN N, WANG L, XI Q, et al.. ITGA7, CD133, ALDH1 are inter-correlated, and linked with poor differentiation, lymph node metastasis as well as worse survival in surgical cervical cancer[J]. J. Obstet. Gynaecol. Res., 2022, 48(4): 1011-1018.
2	MING X Y, FU L, ZHANG L Y, et al.. Integrin α7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma[J/OL]. Nat. Commun., 2016, 7: 13568[2024-08-10]. .
3	LI W, WEI W, HU D, et al.. circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma[J/OL]. Open Med., 2023, 18(1): 20220604[2024-08-10]. .
4	GUAN Y, BHANDARI A, XIA E, et al.. Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition[J]. Acta Biochim. Biophys. Sin., 2020, 52(2): 116-124.
5	CAMPBELL I D, HUMPHRIES M J. Integrin structure, activation, and interactions[J/OL]. Cold Spring Harb. Perspect. Biol., 2011, 3(3): a004994[2024-08-10]. .
6	宁尚昆,马翔宇,孙童,等.整合素在肝细胞癌中的研究进展[J].中华肿瘤防治杂志,2023,30(1):61-66.
	NING S K, MA X Y, SUN T, et al.. Research progress of integrin in hepatocellular carcinoma[J]. Chin. J. Cancer Prev. Treat., 2023, 30(1): 61-66.
7	许斌,褚伟强,万波,等.整合素 α7在肝癌组织中上调表达及对肝癌细胞增殖和迁移的影响[J].临床和实验医学杂志,2017,16(20):2014-2017.
	XU B, CHU W Q, WAN B, et al.. Upregulation of expression of Integrin α7 promotes proliferation and migration of hepatocellular carcinoma[J]. J. Clin. Exp. Med., 2017, 16(20): 2014-2017.
8	GINSBERG M H. Integrin activation[J]. BMB Rep., 2014, 47(12): 655-659.
9	SLACK R J, MACDONALD S J F, ROPER J A, et al.. Emerging therapeutic opportunities for integrin inhibitors[J]. Nat. Rev. Drug Discov., 2022, 21(1): 60-78.
10	HAN S, SEO M H, LIM S, et al.. Decrease in ITGA7 levels is associated with an increase in α-synuclein levels in an MPTP-induced Parkinson's disease mouse model and SH-SY₅Y cells[J/OL]. Int. J. Mol. Sci., 2021, 22(23): 12616[2024-08-10]. .
11	HAN S, LIM S, YEO S. Association between decreased ITGA7 levels and increased muscle α-synuclein in an MPTP-induced mouse model of Parkinson's disease[J/OL]. Int. J. Mol. Sci., 2022, 23(10): 5646[2024-08-10]. .
12	BHANDARI A, XIA E, ZHOU Y, et al.. ITGA7 functions as a tumor suppressor and regulates migration and invasion in breast cancer[J]. Cancer Manag. Res., 2018, 10: 969-976.
13	BAO F, YI J, LIU Y, et al.. Free or fixed state of nHAP differentially regulates hBMSC morphology and osteogenesis through the valve role of ITGA7[J]. Bioact. Mater., 2022, 18: 539-551.
14	BUGIARDINI E, NUNES A M, OLIVEIRA-SANTOS A, et al.. Integrin α7 mutations are associated with adult-onset cardiac dysfunction in humans and mice[J/OL]. J. Am. Heart Assoc., 2022, 11(23): e026494[2024-08-10]. .
15	TOMCZAK K, CZERWIŃSKA P, WIZNEROWICZ M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp. Oncol. Poznan Pol., 2015, 19(1A): 68-77.
16	BARRETT T, WILHITE S E, LEDOUX P, et al.. NCBI GEO: archive for functional genomics data sets: update[J]. Nucleic Acids Res., 2013, 41: 991-995.
17	LI T, FU J, ZENG Z, et al.. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res., 2020, 48(W1): 509-514.
18	GAO J, AKSOY B A, DOGRUSOZ U, et al.. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J/OL]. Sci. Signal., 2013, 6(269): pl1[2024-08-10]. .
19	Consortium GTEx. The Genotype-Tissue Expression (GTEx) project[J]. Nat. Genet., 2013, 45(6): 580-585.
20	CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al.. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649-658.
21	SZKLARCZYK D, GABLE A L, NASTOU K C, et al.. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Res., 2021, 49(D1): 605-612.
22	BARDOU P, MARIETTE J, ESCUDIÉ F, et al.. Jvenn: an interactive Venn diagram viewer[J/OL]. BMC Bioinform., 2014, 15(1): 293[2024-08-10]. .
23	JIAO X, SHERMAN B T, HUANG D W, et al.. DAVID-WS: a stateful web service to facilitate gene/protein list analysis[J]. Bioinform. Oxf. Engl., 2012, 28(13): 1805-1806.
24	YIN W, WANG J, JIANG L, et al.. Cancer and stem cells[J]. Exp. Biol. Med., 2021, 246(16): 1791-1801.
25	CAO M, LI H, SUN D, et al.. Current cancer burden in China: epidemiology, etiology, and prevention[J]. Cancer Biol. Med., 2022, 19(8): 1121-1138.
26	MAKHOV P, JOSHI S, GHATALIA P, et al.. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies[J]. Mol. Cancer Ther., 2018, 17(7): 1355-1364.
27	GAO Q, SUN Z, FANG D. Integrins in human hepatocellular carcinoma tumorigenesis and therapy[J]. Chin. Med. J., 2023, 136(3): 253-268.
28	LEONARDI G C, FALZONE L, SALEMI R, et al.. Cutaneous melanoma: from pathogenesis to therapy (review)[J]. Int. J. Oncol., 2018, 52(4): 1071-1080.

[1]	郭子豪, 裴铁民, 梁德森, 袁帆. 胰岛素生长因子2 mRNA结合蛋白3与肿瘤的相关性研究进展[J]. 生物技术进展, 2021, 11(6): 711-717.
[2]	张文颖,,王思情,张新妍,李庆伟,,李莹莹,. JAK2/STAT3作为新型抗癌药物靶点的研究进展[J]. 生物技术进展, 2021, 11(1): 33-39.
[3]	王婷婷,赵鹏翔,谢飞. 黄芩苷的抗肿瘤作用及机制研究进展[J]. 生物技术进展, 2019, 9(1): 13-20.
[4]	吴尽,肖慧,赵敏蝶,丁新,郑冬,刘学东. SOX9基因在癌症发生发展中作用机制研究进展[J]. 生物技术进展, 2018, 8(5): 397-401.
[5]	李佳腊,张亚婷,谢飞. 氢分子在癌症防治中的应用进展[J]. 生物技术进展, 2016, 6(3): 174-178.
[6]	穆京海,叶舟,张权,尹健. 介孔二氧化硅在癌症化疗药物控释和靶向输送中的应用进展[J]. 生物技术进展, 2016, 6(3): 179-184.
[7]	张爽,郑冬,马月辉. IL-6在代谢类疾病及癌症中的功能研究进展[J]. 生物技术进展, 2015, 5(5): 347-350.

ITGA7基因与人类肿瘤的泛癌分析

Pan Cancer Analysis Between ITGA7 Gene and Human Tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 28

相关文章 7

编辑推荐

Metrics

本文评价